Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 269Neoplasms 148Breast Neoplasms 146Colorectal Neoplasms 128Neoplasm Metastasis 96Prostatic Neoplasms 95Multiple Myeloma 94Ovarian Neoplasms 93Lung Neoplasms 88Squamous Cell Carcinoma of Head and Neck 64Pancreatic Neoplasms 64Recurrence 62Endometrial Neoplasms 58Small Cell Lung Carcinoma 52Melanoma 52Stomach Neoplasms 50Leukemia, Lymphocytic, Chronic, B-Cell 48Carcinoma, Renal Cell 47Leukemia, Myeloid, Acute 46Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 40Urinary Bladder Neoplasms 38Triple Negative Breast Neoplasms 38Parkinson Disease 4, Autosomal Dominant Lewy Body 38Head and Neck Neoplasms 38Lymphoma, Large B-Cell, Diffuse 36Carcinoma, Hepatocellular 35Esophageal Neoplasms 32Lymphoma, Follicular 30Colonic Neoplasms 29

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡